The Justice Department’s April 23 move to shift certain medical marijuana products into Schedule III has yanked a long-running handicap off small cannabis drug developers, and the money crowd is suddenly picking up the phone again. Executives at niche biotechs say the policy change is already reviving talks with venture funds and nudging some companies to consider public listings and fresh private raises this year. For drugmakers and investors, the shift looks like the start of a practical route to U.S.-based trials, easier banking, and, if all goes according to plan, future IPOs.
Federal Shift Nudges Medical Cannabis Into Schedule III
Acting Attorney General Todd Blanche signed an order on April 23 placing FDA-approved marijuana products and products sold under qualifying state medical-marijuana licenses into Schedule III, while launching an expedited process to consider broader rescheduling, according to the Justice Department. The order sets new DEA registration requirements for state licensees and makes clear that the move is limited to products covered by FDA approval or state medical programs. Justice officials framed the shift as a way to strengthen medical research while keeping strict federal controls in place.
Biotechs Start Dialing Investors Again
Industry executives and lawyers say the rescheduling is already loosening long-standing barriers that kept many mainstream investors on the sidelines. As reported by Reuters, Ananda Pharma plans to raise roughly $10 million to $20 million in private funding within months. IGC Pharma is testing a low-dose THC liquid for agitation in Alzheimer’s patients and is weighing a roughly $50 million round later in the year. Avicanna and BRC Therapeutics told Reuters that the federal shift eases reputational headaches and could reopen a path to IPOs on major exchanges for companies running tightly regulated drug programs.
Banking Relief, Tax Twists, And Trial Hurdles
Legal advisers say the change should ease several real-world headaches for medically licensed operators, including basic access to deposit accounts and the ability to deduct ordinary business expenses. An analysis from Holland & Knight notes that the order directs the IRS to consider retrospective relief from Internal Revenue Code Section 280E for qualified state licensees and instructs the DEA to fast-track registrations. At the same time, the firm warns that card networks and many banks are likely to move cautiously. Recreational markets and unlicensed producers remain on a different footing entirely, leaving a patchwork regulatory landscape for companies that straddle both medical and adult-use sides of the business.
Company leaders say the policy pivot has already changed how the market listens. In a company statement, BRC Therapeutics CEO George Hodgin called rescheduling “a watershed moment” and said it has drawn new attention to BRC’s clinical programs, according to BRC Therapeutics materials. That reaction comes against a pretty stark backdrop: so far, only one U.S. product has been cleared by the FDA as a cannabis-derived medicine, the epilepsy drug Epidiolex, as reflected in its FDA label. That scarcity helps explain why traditional pharma investors have mostly steered clear of the sector up to now.
Even with capital tiptoeing back in, the gaps are hard to miss. The DOJ action does not legalize medical or recreational cannabis under federal law, and adult-use products remain in Schedule I for now, as AP noted. The Department and legal analysts have pointed to an expedited DEA hearing, currently scheduled to begin June 29, to consider rescheduling marijuana more broadly. Investors will be watching that timetable closely while banks, payment networks, and regulators sort out their next moves; Holland & Knight has outlined how the hearing schedule and eventual IRS guidance on Section 280E could shape deal structures and cash flow.
For founders and investors, the upshot is a narrow but meaningful reopening of the market. Private rounds and IPO chatter are resurfacing for companies that can point to regulated, FDA-aligned programs, even as operational, tax, and state-law questions stay very much alive. Keep an eye on fundraising announcements from the small biotechs highlighted by Reuters and on regulatory guidance in the run-up to the June DEA hearing.
